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Background: Clinical worsening (CW) relates to poor outcome in pulmonary hypertension (PH) even under treatment. Brain natriuretic peptide 
(BNP) indicates severity of PH but benefit from parenteral treatment is not well defined. We aimed to quantitate the response to intravenous Iloprost 
(ivILO) in patients (pts) with CW of PH and assess the prognostic impact of decrease in BNP with ivILO.
method: 184 pts (F110, M74, age 49±16 yrs) with PH included in a single center EvalUation of PH Risk factors AssociaTEd with Survival - 
EUPHRATES registry. Groups were (n); Idiopathic pulmonary arterial hypertension (IPAH) (44), PAH associated with congenital heart defects (CHD-
APAH) (70), other PAH subgroups (9), group 3 PH (17), group 4 PH (44). 
Results: Pulmonary arterial systolic and mean pressures were 96.3±28 and 60.2±14 mmHg, mean pulmonary and systemic vascular resistance 
(PVR, SVR) and PVR/SVR were 10,6±3,5 and 21+2.5 WU and 0,49±0,2 respectively. All pts received targeted treatment. 1, 3 and 5 year survival (S) 
were 90, 83 and 60%, respectively. Baseline 6 minute walk distance (6MWD) and BNP distribution were divided into tertiles with 250 and 340 m cut 
offs for 6MWD, 89.2 and 464 pg/dl for BNP. CHD-APAH (p<0,001) and functional class (FC)I-II (p<0,05) but not age and sex, were associated with 
higher 5 year S. After 3rd year, FCIII pts showed a trend for increased mortality (M) compared to FC IV (p=NS). Pts in 2nd tertile of 6MWD had higher 
risk of CW and 5 year M compared to other tertiles (p<0.01) and difference became significant after 2nd year. Pts in 2nd BNP tertile showed a time 
dependent trend for increased M (p=NS). Baseline PVR>13 WU (AUC:0,69; 95% CI:0.54-0.85, p<0,05) and PVR/SVR>0.51(AUC:0,76; 95% CI:0.57-
0.94, P<0.05) predicted higher 5 year M. In 312 events of CW to FC IV, ivILO improved Borg dyspnea index, FC, 6MWD (p<0.05) and BNP (474±741 
vs 301±581 pg/dl, p<0.05).The Δ and % decrease in BNP with ivILO did not predict outcome but the ratio of ΔBNP to ivILO infusion duration 
(ΔBNP/ ivILOdur)<4.6 pg/dl days related to lower 5 year S (AUC: 0.70;0.53-0.86,p<0.05). 
conclusion: ivILO may improve clinical status and BNP levels and ΔBNP/ivILOdur<4.6 pg/dl days may reveal resistance to treatment and risk of M 
in CW of PH.
